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bstract
The objective of the study was to develop and validate an analytical method for estimating the stability of duloxetine hydrochloride.
he drug was subjected to the stress conditions prescribed by the International Conference on Harmonization, including hydrolysis,
xidation, photolysis and dry heat. Five degradation products were formed, which were separated by high-performance liquid
hromatography on a Kromasil C18 (150 mm ×  4.6 mm, 5 m) column in a gradient elution programme. The flow rate was 1 ml/min,
nd the detection wavelength was set to 225 nm. The retention time of the drug was 35.7 min, and analysis was completed within
0 min. The method was validated with respect to linearity, precision, accuracy, robustness and limits of detection and quantification
s per the International Conference on Harmonization. The results were linear (r2 = 0.999) over the range 50–400 g/ml and accurate
ver the range 99.41–102.98. The method was robust and rugged, as there was insignificant variation in the results of analysis with
hanges in flow rate and temperature separately.
 2014 Taibah University. Production and hosting by Elsevier B.V. All rights reserved.
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Duloxetine ((+)-(s)-N-methyl-3-(1-naphthyloxy)-3-
thiophen-2-yl)-propan-1-amine) is a selective serotonin
nd norepinephrine reuptake inhibitor used primarily in
he treatment of major depressive disorders and stress
rinary incontinence [1]. Duloxetine is also used to
reat pain and tingling in diabetic neuropathy. Dulox-
tine, also known as LY248686 [2,3], is a potent dual
nhibitor of reuptake of serotonin (5-hydroxytryptamine)∗ Corresponding author. Tel.: +91 9823161187.
E-mail address: d pras anna@yahoo.com (P.A. Datar).
eer review under responsibility of Taibah University.
658-3655 © 2014 Taibah University. Production and hosting by
lsevier B.V. All rights reserved.
ttp://dx.doi.org/10.1016/j.jtusci.2014.06.001and norepinephrine; its effect depends on binding to
human serum albumin. It is approved by the United
States Food and Drug Administration for the treatment
of diabetic neuropathic pain.
Duloxetine hydrochloride is a highly lipophilic com-
pound with strong base properties and a pKa of 9.5.
Its structure is shown in Fig. 1. Phenolic impurities in
duloxetine hydrochloride samples have been identified
by mass spectrometry, nuclear magnetic resonance spec-
troscopy and X-ray analysis [4–6].
The purity of a drug product is determined on the
basis of the percentage of the labelled amount of active
pharmaceutical ingredient found in it by a suitable ana-
lytical method, which provides evidence for specificity,
linearity range, accuracy, precision, detection limit,
quantification limit, ruggedness and robustness of the
method for regulatory purposes. High-performance liq-
uid chromatography (HPLC) is the established technique
for separating non-volatile organic compounds, drugs,
metabolites and toxic residues by isocratic and gradient
elution. Reverse-phase, ion-pair, ion and ion exchange
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9 h. The study under alkaline conditions was carried out
◦Fig. 1. Structure of duloxetine hydrochloride.
HPLC and sometimes size exclusion chromatography
are used conventionally. If the mobile phase remains
constant throughout HPLC separation, the separation is
deemed to be isocratic, while if the sample contains com-
ponents of a wide range of polarities, gradient elution is
the only way to elute all the compounds in the sample in
a reasonable time while maintaining peak resolution by
changing the ratio of polar to non-polar compounds in
the mobile phase during the sample run. For a reverse-
phase gradient, the solvent is initially relatively polar
and slowly becomes more non-polar. A sample contain-
ing compounds with a wide range of polarities can be
separated by gradient elution in a shorter time with-
out loss of resolution in the earlier peaks or excessive
broadening of later peaks; it is more difficult to main-
tain a constant flow rate with continuous changes in
mobile phase composition. Gradient elution is used in
preparative and large-scale chromatography for separa-
tion.
The parent drug stability test guideline Q1A (R2)
issued by the International Conference on Harmoniza-
tion (ICH) suggests that stress studies be carried out on
a drug to establish its inherent stability [7], i.e. the extent
to which a product retains the same properties and char-
acteristics it had at the time of packaging, within the
specified limits, throughout storage and use [8,9]. Sta-
bility testing thus indicates the effect of environmental
factors on the quality of a drug or a formulated prod-
uct and is used to predict its shelf life, determine the
proper storage conditions and suggest labelling instruc-
tions. Various analytical methods have been reported
namely, HPLC [10–17], high-performance thin-layer
chromatography [18,19], ultra-performance liquid chro-
matography [20] and liquid chromatography–tandem
mass spectrometry [21–23]. Degradation studies have
also been reported [24–27] under thermal, acidic, alka-
line, neutral hydrolysis and oxidative photolytic stress
conditions.niversity for Science 8 (2014) 357–363
2.  Experimental
2.1.  Materials
Pure duloxetine hydrochloride was donated by Uni-
mark Remedies Ltd., Mumbai, India. Acetonitrile
(HPLC grade) was purchased from Thomas Baker,
Mumbai. Other chemicals used were of analytical grade.
Ultrapure (double-distilled) water was obtained from a
water purification unit.
2.2.  Instrumentation
The HPLC instrument used was a Shimadzu LC-20
Prominence (Shimadzu, Kyoto, Japan) system equipped
with an LC-20AD binary pump, a SPD-M20A photo-
diode array detector and a rheodyne injector. The
output signal was monitored and processed with liquid
chromatography solution software (Shimadzu, Kyoto,
Japan). The injection volume was 20 l, and chromato-
graphic separation was achieved on a Kromasil C18
(150 mm × 4.6 mm), 5 m particle size column.
2.3.  Preparation  of  standard  stock  solution
A standard stock solution of the drug was prepared
by dissolving pure drug in the mobile phase, i.e. 100 mg
duloxetine hydrochloride in 100 ml methanol. The solu-
tion was sonicated and filtered through Whatman filter
paper, and the resulting solution was further diluted with
the mobile phase to a concentration of 1000 g/ml.
2.4.  Preparation  of  mobile  phase
Solvent A: Potassium dihydrogen phosphate (0.68 g)
was dissolved in 500 ml water, 0.1% triethylamine was
added, and the pH was adjusted to 3.5 with orthophos-
phoric acid. Triethylamine was used to reduce tailing
of the analyte. Methanol was added in proportions of
8.5:1.5. The solution was filtered through a 0.45-m
nylon 66 membrane filter and was further degassed in
a sonicator for about 15 min. Solvent B was Methanol.
2.5.  Degradation  studies
All stress decomposition studies were performed at
an initial drug concentration of 1000 g/ml in methanol.
Acid hydrolysis was performed in 0.5 N HCl at 80 ◦C forin 1 N NaOH at 80 C for 4 h. For the study under neutral
conditions, drug dissolved in water was heated at 80 ◦C
for 4 h. Oxidative stress studies were carried out at room
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Table 1
Gradient programme for separation studies.
Time Methanol solvent Phosphate buffer solvent
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emperature with 10%, 15% and 30% hydrogen peroxide
or 24 h. For the photo-degradation studies, the solutions
ere exposed for 1 h in a chamber with 200–400 nm
ltra-violet light and visible spectra (60,000–70,000 lx)
or 10 h. Suitable controls were kept in the dark. Sam-
les were withdrawn at appropriate times and analysed
y HPLC after suitable dilution [7,24–27]. Peak purity
nd mass balance were monitored for each degradation
ondition.
.6.  Separation  studies
Before method development, various physicochemi-
al parameters must be known, such as the pKa, log P,
olubility, absorptivity and wavelength maximum of the
rug. The pKa is important as most pH-related changes
n retention occur at pH values within 1.5 units of the
Ka value [28]. Studies were first conducted on all reac-
ion solutions individually and then on a mixture of the
olutions, in which decomposition was observed. Sepa-
ation was achieved by gradient elution. Initial studies
n individual reaction solutions were conducted with
ethanol:potassium dihydrogen phosphate buffer and
riethylamine (0.1%) (pH adjusted to 3.5 with orthophos-
horic acid), with the gradient programme shown in
able 1.
.7.  Validation  of  the  method  [29,30]
.7.1.  Linearity  and  range
The stock solution was diluted with mobile phase
o prepare solutions containing 50–400 g/ml of the
rug. Each concentration was injected six times onto the
PLC column, and the peak areas were noted and plot-
ed against the corresponding concentration to obtain a
alibration curve.
.7.2.  Precision
Injections of three concentrations (100, 200 and
00 g/ml), repeated six times, were given on the same
ay, and the relative standard deviation was calculated
o determine intra-day precision.niversity for Science 8 (2014) 357–363 359
2.7.3.  Accuracy
Recovery studies by the standard addition method
were performed to determine the accuracy of the method,
with three concentrations (50%, 100% and 150%) of
spiked drug.
2.7.4. Speciﬁcity  and  selectivity
The specificity of the method for the drug was estab-
lished by determining interference (if any) from solvent
or degradation products, with resolution of the drug peak
from the nearest resolving peaks. Overall selectivity was
established by determining the purity of the peak.
2.7.5. Robustness
The effects of varying the mobile phase composition,
flow rate and wavelength were studied.
2.7.6. Limits  of  detection  and  quantiﬁcation
The limit of detection (LOD) is defined as the low-
est concentration of an analyte that can be detected in a
sample, whereas the limit of quantification (LOQ) is the
lowest concentration of an analyte that can be determined
with acceptable precision and accuracy in a sample under
the stated operational conditions. LOD and LOQ were
calculated according to the formulae given in the ICH
guidelines.
3.  Results  and  discussion
HPLC studies on duloxetine hydrochloride under
different stress conditions suggested the following
degradation behaviour. The drug was found to be sus-
ceptible to acid hydrolysis (0.5 N HCl, 9 h), with 5–16%
degradation when heated at 80 ◦C, but was stable in neu-
tral hydrolysis (water, 4 h). It was stable to degradation
with 10%, 15% and 30% hydrogen peroxide at room
temperature for 24 h.
Three major degradation products were observed
after exposure of drug solution to ultra-violet light for
33 min, with five major degradation peaks at retention
times of 3.5 min (Degr. 1), 12.7 min (Degr. 2), 25.4 min
(Degr. 3), 30.6 min (Degr. 4) and 32.4 min (Degr. 5)
(Fig. 2). The spectral data showed that acid Degr. 3 and
photolytic Degr. 1 were identical (Fig. 3).
The solid-state studies showed that duloxetine
hydrochloride is stable to the effect of temperature.
When the drug powder was exposed to dry heat at 80 ◦C
for 8 days, no decomposition was seen.The method was optimised to separate the major
degradation products formed under various conditions,
and resolution was checked with a mixture of the degra-
dation solutions to confirm the separation. The resulting
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s and acFig. 2. Chromatogram of degradation product
chromatograms are shown in Fig. 3 and Fig. 4. They
indicate that the method successfully separated the drug
from all degradation products.The method was validated as per the ICH guidelines.
The linearity of the peak area response was determined
by injecting samples of 20 l of dilutions of the standard
Fig. 3. Ultra-violet spectra of acid Dtive pharmaceutical ingredient of duloxetine.
stock solution onto the column at a flow rate 1.0 ml/min.
Each dilution was injected six times. Drug in the eluates
was monitored at 225 nm, and the corresponding chro-
matograms were obtained. The regression of the plot
was obtained by least squares regression. The mean peak
areas were calculated from these chromatograms, and a
egr. 3 and photolytic Degr. 1.
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Fig. 4. Chromatogram of acid and photolytic degradation products.
Table 2
Linearity of peak areas of duloxetine hydrochloride.
Series no. Concentration (g/ml) Peak area Relative SD (%)
Injection 1 Injection 2 Injection 3 Average
1 50 7,988,246 8,112,894 8,057,470 8,052,870 0.77
2 100 16,381,354 16,439,857 16,408,360 16,409,857 0.17
3 200 34,779,684 34,798,639 34,787,593 34,788,639 0.02
4 300 52,385,228 51,484,075 51,482,922 51,784,075 1.00
5 400 69,065,440 69,065,150 69,064,860 69,065,150 0.0004
Table 3
Intra-day precision.
Concentration (g/ml) Peak area Mean area Found concentration
(g/ml)
SD Relative SD
Morning Afternoon Evening
100 16,257,544 16,382,795 16,575,412 16,405,250 100.02 ± 0.976 160,119.3 0.976
2  34,985,316 198.87 ± 0.002 397.2625 0.001
3  52,045,502 299.35 ± 0.116 20,136.285 0.038
p
(
c
t
d
i00 34,985,721 34,985,299 34,984,927
00 52,039,032 52,068,078 52,029,396
lot of concentration over the peak area was obtained
Table 2).
The peak area was plotted against the corresponding
oncentrations to obtain the calibration curve (Fig. 5).
As the relative SD for inter-day precision was less
han 2, it can be concluded that the method is repro-
ucible (Table 3).
Accuracy tested by the standard addition method was
n the range of 99.41–102.48% (Tables 4 and 5).Fig. 5. Calibration curve of duloxetine hydrochloride on HPLC.
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Table 4
Inter-day precision.
Concentration (g/ml) Peak area Mean area Found concentration
(g/ml)
SD Relative SD
Day 1 Day 2 Day 3
100 16,257,854 16,385,972 16,366,248 16,336,691.33 99.55 ± 0.42 68,983.71467 0.422
200 34,971,275 34,982,589 34,975,678 34,976
300 52,040,586 52,042,568 52,032,546 52,038
Table 5
Accuracy.
Actual concentration
(g/ml)
Measured concentration
(g/ml); relative SD
Recovery (%)
50 50.14 ± 0.45; 0.56 100.28
100 100.98 ± 1.93; 1.6 102.98
150 149.12 ± 0.69; 0.67 99.41
Table 6
Robustness.
Flow rate (ml/min) Wavelength (nm)
0.95 1.00 1.05 223 225 227
[
Chromatogr. Relat. Technol. 19 (1996) 1631–1641.Relative
SD
0.3988 0.3345 0.3115 0.3286 0.3345 0.3158
As small deliberate changes did not result in signifi-
cant changes in the peak area, the method is robust and
resistant to such changes (Table 6).
The LOD and LOQ were 1.17 and 3.57 g/ml, respec-
tively, as confirmed by preparing concentrations below
and above these values.
4.  Conclusion
The HPLC method reported here is accurate, precise,
reproducible, specific and stable. There is allowable vari-
ation in flow rate, temperature, pH and mobile phase
composition, which indicate that the method is robust.
The low relative SD for the percentage assay of the test
preparation shows that the proposed method is rugged.
This study shows that the drug is highly sensitive to
degradation with acid and photolytic stress but stable in
dry heat and oxidative conditions. This method allows
separation of all degradation products formed under a
variety of conditions.Acknowledgements
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